Search research articles
Contact Us
Filters
Showing results (171-180 of 188) with videos related to
Page
of 19
Sort By:
The American Journal of Pathology
|
November 7, 1999
Fluctuation of HER2 expression in breast carcinomas during the menstrual cycle
A Balsari, P Casalini, E Tagliabue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 24, 2001
Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables
S Ménard, P Valagussa, S Pilotti, et al.
Advances in Experimental Medicine and Biology
|
January 1, 1988
Monoclonal antibodies as prognostic indicators of tumor progression in breast cancer
M I Colnaghi, R Agresti, S Ménard, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
June 22, 1999
Sentinel node biopsy and selective lymph node dissection in cutaneous melanoma patients
L Lenisa, M Santinami, F Belli, et al.
Human Pathology
|
April 1, 1991
Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme
C Clemente, A J Cochran, D E Elder, et al.
Annals of Surgical Oncology
|
July 14, 2000
Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience
N Cascinelli, F Belli, M Santinami, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 14, 2006
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma
E Bajetta, M Del Vecchio, P Nova, et al.
Melanoma Research
|
December 22, 1999
Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma)
M R Sertoli, P Queirolo, E Bajetta, et al.
Lasers in Surgery and Medicine
|
January 1, 1983
Laser oncology in Italy: experimental research and clinical applications at the National Cancer Institute, Milan
H Emanuelli, G Bandieramonte, R Marchesini, et al.
Human Gene Therapy
|
December 28, 1999
Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells
F Arienti, F Belli, F Napolitano, et al.
Page
of 19
Search research articles
Search
Showing results (171-180 of 188) with videos related to
Sort By:
Page
of 19
The American Journal of Pathology
|
November 7, 1999
Fluctuation of HER2 expression in breast carcinomas during the menstrual cycle
A Balsari, P Casalini, E Tagliabue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 24, 2001
Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables
S Ménard, P Valagussa, S Pilotti, et al.
Advances in Experimental Medicine and Biology
|
January 1, 1988
Monoclonal antibodies as prognostic indicators of tumor progression in breast cancer
M I Colnaghi, R Agresti, S Ménard, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
June 22, 1999
Sentinel node biopsy and selective lymph node dissection in cutaneous melanoma patients
L Lenisa, M Santinami, F Belli, et al.
Human Pathology
|
April 1, 1991
Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme
C Clemente, A J Cochran, D E Elder, et al.
Annals of Surgical Oncology
|
July 14, 2000
Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience
N Cascinelli, F Belli, M Santinami, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 14, 2006
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma
E Bajetta, M Del Vecchio, P Nova, et al.
Melanoma Research
|
December 22, 1999
Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma)
M R Sertoli, P Queirolo, E Bajetta, et al.
Lasers in Surgery and Medicine
|
January 1, 1983
Laser oncology in Italy: experimental research and clinical applications at the National Cancer Institute, Milan
H Emanuelli, G Bandieramonte, R Marchesini, et al.
Human Gene Therapy
|
December 28, 1999
Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells
F Arienti, F Belli, F Napolitano, et al.
Page
of 19